Compassionate Use of Remdesivir for Patients with Severe Covid-19
Authors:
- Jonathan GreinJGJonathan Grein
- Norio OhmagariNONorio Ohmagari
- Daniel ShinDSDaniel Shin
- George DiazGDGeorge Diaz
- Erika AspergesEAErika Asperges
- Antonella CastagnaACAntonella Castagna
- Torsten FeldtTFTorsten Feldt
- Gary GreenGGGary Green
- Margaret L. GreenMGMargaret L. Green
- François-Xavier LescureFLFrançois-Xavier Lescure
- Emanuele NicastriENEmanuele Nicastri
- Rentaro OdaRORentaro Oda
Top Cited Papers
- 11 June 2020
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 382 (24) , 2327-2336
Abstract
Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day. Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation. In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)Keywords
Funding Information
- Gilead Sciences (N/A)
This publication has 26 references indexed in Scilit:
- Of chloroquine and COVID-19Antiviral Research, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Covid-19 — Navigating the UnchartedNew England Journal of Medicine, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- First Case of 2019 Novel Coronavirus in the United StatesNew England Journal of Medicine, 2020
- Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infectionProceedings of the National Academy of Sciences, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoVNature Communications, 2020
- A Randomized, Controlled Trial of Ebola Virus Disease TherapeuticsNew England Journal of Medicine, 2019
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronavirusesScience Translational Medicine, 2017